Enquirer Consulting Group

Reachable Buyer Map

Prepared for Richard Thorpe, Veranova · United States · August 2026
Here is the map. Outsourced development and manufacturing work has two buyers in every account who arrive at different times: the scientific team that qualifies a partner, and the commercial team that signs the agreement. In this market, first contact usually happens at a conference or through someone who already holds the relationship, which is why the reachable list always looks smaller than the real one. This page counts the United States side of it.
Commercial-stage pharmaceutical and medicine manufacturers
Companies that already sell a product and buy outside capacity to keep a pipeline moving. The clearest fit for custom work at scale. Qualification is slow and technical, and the relationship that follows is measured in years rather than in orders, which is what makes the segment worth working by name.
Who signs: head of external manufacturing, VP of technical operations, head of CMC, chief scientific officer, and the sourcing lead on the agreement itself.
1,350 to 1,400
US employers registered under pharmaceutical and medicine manufacturing; about 320 carry 250 or more people on the plan
Scientific research and development companies
Where new molecules come from, and the group most likely to need development work long before it needs volume. Worth being straight about a limit: the public register does not separate life science research from research of every other kind, so this count is the outer edge of that layer rather than a clean list of it.
Who signs: founder or CEO at the smaller end, chief scientific officer, VP of process chemistry, head of CMC.
4,400 to 4,500
US employers registered under scientific research and development services; about 450 at 250 people or more
Drug distributors and generic suppliers
The buyers for catalog products rather than for a development program. Reference standards and generic actives move through this layer, and the decision is commercial rather than scientific, which makes it a shorter conversation with a different person at the end of it.
Who signs: VP of sourcing, category manager, quality lead, general manager.
600 to 650
US employers registered as drug and pharmaceutical wholesalers; about 80 at 250 people or more
Clinical-stage companies below the filing line
Small and virtual companies that outsource everything and carry a handful of employees. They are the origin of a large share of first programs and they are the hardest group to enumerate, because a company with no benefit plan does not appear in the register at all. Named one at a time rather than counted.
Who signs: the CEO, the head of CMC where one exists, and the consultant who runs manufacturing on their behalf.
No public count
not published in any public employer register; identified individually

Where the openings are

1
The counted market is small enough to work by name. The three segments above come to roughly 6,350 to 6,550 US employers, and about 850 of them carry 250 or more people. That is not a market you campaign at. It is a list you cover.
2
The scientific buyer and the commercial buyer are rarely the same person. A conversation that starts with process chemistry ends with a sourcing lead who was never in the room, and a conversation that starts commercially stalls until a technical team blesses it. Reaching both seats inside the same account, in the same quarter, is a channel design question rather than a scientific one.
3
Conferences select for who traveled this year. The companies most likely to need a partner are the ones whose program just moved into a phase where their current route stops working, and that moment is not synchronized with an events calendar. Watching a few thousand named companies for that trigger is mechanical work, and it is the part a relationship channel cannot do.
4
The early clinical layer is the one bought lists miss. A company with no benefit plan is invisible to the register, so anyone buying a ready-made list of pharmaceutical companies reaches the commercial tier and misses the tier that is shopping for a first route. That segment stays open because it takes identification rather than purchase.
Built from public federal registry data covering US employers that file a benefit plan, current to the 2024 filing year. Counts are banded deliberately. Headcount bands use plan participants as a proxy, so they indicate scale rather than an exact staff count. Owner-only and very small employers are not published in this data, which is why the early clinical layer is described rather than counted. Sector codes are self-reported by the companies themselves. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com